Novel radioimmunopharmaceuticals for cancer imaging and therapy

Current Opinion in Investigational Drugs

Volumn 9, Issue 12, 2008, Pages 1302-1316

  Sharkey, R M ^a   Goldenberg, D M ^a  

^a CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

Author keywords

Antibody engineering; Cancer; mAb; Pretargeting; Radioimmunodetection; Radioimmunotherapy; Radionuclides

Indexed keywords

ACTINIUM 225; AFFIBODY; ANTIBODY; APTAMER; AT 211; BIOTIN; BISMUTH 213; BISPECIFIC ANTIBODY; CAPROMAB PENDETIDE IN 111; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY F 18; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY IN 111; COPPER 64; COPPER 67; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; GALLIUM 67; GALLIUM 68; INDIUM 111; IODINE 123; IODINE 125; IODINE 131; LUTETIUM 177; RADIOISOTOPE; RHENIUM 186; RHENIUM 188; SYNTHETIC HIGH AFFINITY LIGAND; TECHNETIUM 99M; UNCLASSIFIED DRUG; UNINDEXED DRUG; YTTRIUM 90;

ALPHA RADIATION; ANTIBODY ENGINEERING; ANTIGEN BINDING; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER THERAPY; DRUG HALF LIFE; DRUG TARGETING; HUMAN; IMAGING; ISOTOPE LABELING; NONHUMAN; RADIOIMMUNOASSAY; RADIOIMMUNOTHERAPY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ANIMALS; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; RADIOGRAPHIC IMAGE ENHANCEMENT; RADIOIMMUNOTHERAPY; RADIOPHARMACEUTICALS;

EID: 57349162730     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (182)

1. Pressman D, Korngold L: The in vivo localization of anti-Wagner-osteogenic-sarcoma antibodies. Cancer (1953) 6(3):619-623.
2. Bale WF, Spar IL: Studies directed toward the use of antibodies as carriers of radioactivity for therapy. Adv Biol Med Phys (1957) 5:285-356.
3. Goldenberg DM, Sharkey RM, Barbet J, Chatal JF: Radioactive antibodies: Selective targeting and treatment of cancer and other diseases. Appl Radiol (2007) 36(4):10-29.
4. Baxter LT, Jain RK: Transport of fluid and macromolecules in tumors. III. Role of binding and metabolism. Microvasc Res (1991) 41(1):5-23.
5. Baxter LT, Zhu H, Mackensen DG, Jain RK: Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice. Cancer Res (1994) 54(6):1517-1528.
6. Fujimori K, Covell DG, Fletcher JE, Weinstein JN: A modeling analysis of monoclonal antibody percolation through tumors: A binding-site barrier. J Nucl Med (1990) 31(7):1191-1198.
7. Thurber GM, Schmidt MM, Wittrup KD: Antibody tumor penetration: Transport opposed by systemic and antigen-mediated clearance. Adv Drug Deliv Rev (2008) 60(12):1421-1434. • A review of the various barriers that affect tumor targeting.
8. Davda JP, Jain M, Batra SK, Gwilt PR, Robinson DH: A physiologically based pharmacokinetic (PBPK) model to characterize and predict the disposition of monoclonal antibody CC49 and its single-chain Fv constructs. Int Immunopharmacol (2008) 8(3):401-413.
9. Jain M, Venkatraman G, Batra SK: Optimization of radioimmunotherapy of solid tumors: Biological impediments and their modulation. Clin Cancer Res (2007) 13(5):1374-1382.
10. Beckman RA, Weiner LM, Davis HM: Antibody constructs in cancer therapy: Protein engineering strategies to improve exposure in solid tumors. Cancer (2007) 109(2):170-179.
11. Jain RK, Baxter LT: Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: Significance of elevated interstitial pressure. Cancer Res (1988) 48(24 Pt 1):7022-7032.
12. Colcher D, Pavlinkova G, Beresford G, Booth BJ, Choudhury A, Batra SK: Pharmacokinetics and biodistribution of genetically-engineered antibodies. Q J Nucl Med (1998) 42(4):225-241.
13. Wu AM, Olafsen T: Antibodies for molecular imaging of cancer. Cancer J (2008) 14(3):191-197. • A review of the contributions that molecular biology has made to the development of different types of engineered antibodies.
14. Olafsen T, Kenanova VE, Wu AM: Tunable pharmacokinetics: Modifying the in vivo half-life of antibodies by directed mutagenesis of the Fc fragment. Nat Protoc (2006) 1(4):2048-2060.
15. Behr TM, Sharkey RM, Sgouros G, Blumenthal RD, Dunn RM, Kolbert K, Griffiths GL, Siegel JA, Becker WS, Goldenberg DM: Overcoming the nephrotoxicity of radiometal-labeled immunoconjugates: Improved cancer therapy administered to a nude mouse model in relation to the internal radiation dosimetry. Cancer (1997) 80(Suppl 12):2591-2610.
16. Behr TM, Béhé M, Sgouros G: Correlation of red marrow radiation dosimetry with myelotoxicity: Empirical factors influencing the radiation-induced myelotoxicity of radiolabeled antibodies, fragments and peptides in preclinical and clinical settings. Cancer Biother Radiopharm (2002) 17(4):445-464.
17. Peterson JJ, Meares CF: Enzymatic cleavage of peptide-linked radiolabels from immunoconjugates. Bioconjug Chem (1999) 10(4):553-557.
18. Meares CF, McCall MJ, Deshpande SV, DeNardo SJ, Goodwin DA: Chelate radiochemistry: Cleavable linkers lead to altered levels of radioactivity in the liver. Int J Cancer Suppl (1988) 2:99-102.
19. 111In] DOTATOC in rats: Influence of inhibitors of the organic ion transport and diuretics. Eur J Nucl Med Mol Imaging (2007) 34(12):2129-2134.
20. Li L, Olafsen T, Anderson AL, Wu A, Raubitschek AA, Shively JE: Reduction of kidney uptake in radiometal labeled peptide linkers conjugated to recombinant antibody fragments. Site-specific conjugation of DOTA-peptides to a Cys-diabody. Bioconjug Chem (2002) 13(5):985-995.
21. Behr TM, Goldenberg DM, Becker W: Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: Present status, future prospects and limitations. Eur J Nucl Med (1998) 25(2):201-212.
22. 111In-octreotide in mice and rats. J Nucl Med (2006) 47(3):528-533.
23. Slavin-Chiorini DC, Kashmiri SV, Lee HS, Milenic DE, Poole DJ, Bernon E, Schlom J, Hand PH: A CDR-grafted (humanized) domain-deleted antitumor antibody. Cancer Biother Radiopharm (1997) 12(5):305-316.
24. Mueller BM, Reisfeld RA, Gillies SD: Serum half-life and tumor localization of a chimeric antibody deleted of the CH2 domain and directed against the disialoganglioside GD2. Proc Natl Acad Sci USA (1990) 87(15):5702-5705.
25. Slavin-Chiorini DC, Kashmiri SV, Schlom J, Calvo B, Shu LM, Schott ME, Milenic DE, Snoy P, Carrasquillo J, Anderson K, Horan Hand P: Biological properties of chimeric domain-deleted anticarcinoma immunoglobulins. Cancer Res (1995) 55(Suppl 23):5957s-5967s.
26. Leung SO, Qu Z, Hansen HJ, Shih LB, Wang J, Losman MJ, Goldenberg DM, Sharkey RM: The effects of domain deletion, glycosylation, and long IgG3 hinge on the biodistribution and serum stability properties of a humanized IgG1 immunoglobulin, hLL2, and its fragments. Clin Cancer Res (1999) 5(Suppl 10):3106s-3117s.
27. H2 region. Cancer Biother Radiopharm (2005) 20(5):502-513.
28. Lawrence LJ, Kortt AA, Iliades P, Tulloch PA, Hudson PJ: Orientation of antigen binding sites in dimeric and trimeric single-chain Fv antibody fragments. FEBS Lett (1998) 425(3):479-484.
29. Hudson PJ, Kortt AA: High avidity scFv multimers; diabodies and triabodies. J Immunol Methods (1999) 231(1-2):177-189. • A review of the contributions that molecular biology has made in the development of different types of engineered antibodies.
30. Wu AM, Yazaki PJ: Designer genes: Recombinant antibody fragments for biological imaging. Q J Nucl Med (2000) 44(3):268-283.
31. Holliger P, Hudson PJ: Engineered antibody fragments and the rise of single domains. Nat Biotechnol (2005) 23:1126-1136.
32. Power BE, Kortt AA, Hudson PJ: Generation of recombinant multimeric antibody fragments for tumor diagnosis and therapy. Methods Mol Biol (2003) 207:335-350.
33. Todorovska A, Roovers RC, Dolezal O, Kortt AA, Hoogenboom HR, Hudson PJ: Design and application of diabodies, triabodies and tetrabodies for cancer targeting. J Immunol Methods (2001) 248(1-2):47-66.
34. Yazaki PJ, Wu AM: Construction and characterization of minibodies for imaging and therapy of colorectal carcinomas. Methods Mol Biol (2003) 207:351-364.
35. Roopenian DC, Akilesh S: FcRn: The neonatal Fc receptor comes of age. Nat Rev Immunol (2007) 7(9):715-725.
36. Presta LG: Molecular engineering and design of therapeutic antibodies. Curr Opin Immunol (2008) 20(4):460-470.
37. Jaggi JS, Carrasquillo JA, Seshan SV, Zanzonico P, Henke E, Nagel A, Schwartz J, Beattie B, Kappel BJ, Chattopadhyay D, Xiao J et al: Improved tumor imaging and therapy via i.v. IgG-mediated time-sequential modulation of neonatal Fc receptor. J Clin Invest (2007) 117(9):2422-2430.
38. Stork R, Zettlitz KA, Müller D, Rether M, Hanisch FG, Kontermann RE: N-glycosylation as novel strategy to improve pharmacokinetic properties of bispecific single-chain diabodies. J Biol Chem (2008) 283(12):7804-7812.
39. Millward TA, Heitzmann M, Bill K, Längle U, Schumacher P, Forrer K: Effect of constant and variable domain glycosylation on pharmacokinetics of therapeutic antibodies in mice. Biologicals (2008) 36(1):41-47.
40. Raju TS, Briggs JB, Borge SM, Jones AJ: Species-specific variation in glycosylation of IgG: Evidence for the species-specific sialylation and branch-specific galactosylation and importance for engineering recombinant glycoprotein therapeutics. Glycobiology (2000) 10(5):477-486.
41. Li L, Yazaki PJ, Anderson AL, Crow D, Colcher D, Wu AM, Williams LE, Wong JY, Raubitschek A, Shively JE: Improved biodistribution and radioimmunoimaging with poly(ethylene glycol)-DOTA-conjugated anti-CEA diabody. Bioconjug Chem (2006) 17(1):68-76.
42. Yazaki PJ, Kassa T, Cheung CW, Crow DM, Sherman MA, Bading JR, Anderson AL, Colcher D, Raubitschek A: Biodistribution and tumor imaging of an anti-CEA single-chain antibody-albumin fusion protein. Nucl Med Biol (2008) 35(2):151-158. • The positive effects of fusing albumin to smaller antibody constructs are described for antibody targeting.
43. Stork R, Müller D, Kontermann RE: A novel trifunctional antibody fusion protein with improved pharmacokinetic properties generated by fusing a bispecific single-chain diabody with an albumin-binding domain from streptococcal protein G. Protein Eng Des Sel (2007) 20(11):569-576.
44. Müller D, Karle A, Meissburger B, Höfig I, Stork R, Kontermann RE: Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin. J Biol Chem (2007) 282(17):12650-12660.
45. Tijink BM, Laeremans T, Budde M, Stigter-van Walsum M, Dreier T, de Haard HJ, Leemans CR, van Dongen GA: Improved tumor targeting of anti-epidermal growth factor receptor nanobodies through albumin binding: Taking advantage of modular nanobody technology. Mol Cancer Ther (2008) 7(8):2288-2297.
46. DeNardo GL, Hok S, Van Natarajan A, Cosman M, DeNardo SJ, Lightstone FC, Mirick GR, Yuan A, Perkins J, Sysko VV, Lehmann J et al: Characteristics of dimeric (bis) bidentate selective high affinity ligands as HLA-DR10 β antibody mimics targeting non-Hodgkin's lymphoma. Int J Oncol (2007) 31(4):729-740.
47. Perkins AC, Missailidis S: Radiolabelled aptamers for tumor imaging and therapy. Q J Nucl Med Mol Imaging (2007) 51(4):292-296.
48. Hicke BJ, Stephens AW, Gould T, Chang YF, Lynott CK, Heil J, Borkowski S, Hilger CS, Cook G, Warren S, Schmidt PG: Tumor targeting by an aptamer. J Nucl Med (2006) 47(4):668-678. • A demonstration of successful use of a synthetic aptamer for targeting cancer.
49. 18F-fluorobenzaldehyde via oxime chemistry. Mol Imaging Biol (2008) 10(4):177-181.
50. Orlova A, Feldwisch J, Abrahmsen L, Tolmachev V: Update: Affibody molecules for molecular imaging and therapy for cancer. Cancer Biother Radiopharm (2007) 22(5):573-584.
51. Orlova A, Nilsson FY, Wikman M, Widstrom C, Stahl S, Carlsson J, Tolmachev V: Comparative in vivo evaluation of technetium and iodine labels on an anti-HER-2 affibody for single-photon imaging of HER-2 expression in tumors. J Nucl Med (2006) 47(3):512-519.
52. 177Lu-labeled HER-2-specific affibody molecule. Cancer Res (2007) 67(6):2773-2782.
53. 99mTc-labeled divalent and tetravalent CC49 single-chain Fvs: Novel imaging agents for rapid in vivo localization of human colon carcinoma. J Nucl Med (2001) 42(10):1519-1527.
54. 99mTc-labeled human recombinant anti-ED-B fibronectin antibody fragments. J Nucl Med (2006) 47(10):1707-1716.
55. 99mtechnetium-labeled single-chain Fv fragments against high molecular weight melanoma-associated antigen. Clin Cancer Res (2000) 6(12):4921-4931.
56. Pietersz GA, Patrick MR, Chester KA: Preclinical characterization and in vivo imaging studies of an engineered recombinant technetium-99m-labeled metallothionein-containing anti-carcinoembryonic antigen single-chain antibody. J Nucl Med (1998) 39(1):47-56.
57. Griffiths GL, Goldenberg DM, Jones AL, Hansen HJ: Radiolabeling of monoclonal antibodies and fragments with technetium and rhenium. Bioconjug Chem (1992) 3(2):91-99.
58. 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT. J Nucl Med (2008) 49(5):788-795.
59. 99mTc-labeled EGFR-specific nanobody for in vivo monitoring of EGFR expression. Mol Imaging Biol (2008) 10(3):167-175.
60. 123I-labeled 80-kilodalton engineered anticarcinoembryonic antigen antibody fragment (cT84.66 minibody) in patients with colorectal cancer. Clin Cancer Res (2004) 10(15):5014- 5021.
61. 18F-labeled T84.66 anti-carcinoembryonic antigen diabody. J Nucl Med (2007) 48(2):304-310.
62. 124I anti-CEA monoclonal antibody in tumor-bearing mice. Cancer Biother Radiopharm (2008) 23(4):399-409.
63. Bakir MA, Eccles S, Babich JW, Aftab N, Styles J, Dean CJ, Lambrecht RM, Ott RJ: c-erbB2 protein overexpression in breast cancer as a target for PET using iodine-124-labeled monoclonal antibodies. J Nucl Med (1992) 33(12):2154-2160.
64. Divgi CR, Pandit-Taskar N, Jungbluth AA, Reuter VE, Gonen M, Ruan S, Pierre C, Nagel A, Pryma DA, Humm J, Larson SM et al: Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: A phase I trial. Lancet Oncol (2007) 8(4):304-310.
65. Larson SM, Pentlow KS, Volkow ND, Wolf AP, Finn RD, Lambrecht RM, Graham MC, Di Resta G, Bendriem B, Daghighian F, Yeh SD et al: PET scanning of iodine-124-3F9 as an approach to tumor dosimetry during treatment planning for radioimmunotherapy in a child with neuroblastoma. J Nucl Med (1992) 33(11):2020-2023.
66. 124I-CDR-grafted humanized A33 monoclonal antibody. J Nucl Med (2001) 42(5):764-769.
67. 124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice. J Nucl Med (2003) 44(12):1962-1969.
68. 131I-radioimmunotherapy. Eur J Nucl Med Mol Imaging (2004) 31(12):1645-1652.
69. 68Ga-PET: A powerful generator-based alternative to cyclotron-based PET radiopharmaceuticals. Contrast Media Mol Imaging (2008) 3(2):67-77.
70. 68Ga- radiolabeled bivalent hapten-peptidechelate conjugates. J Nucl Med (2004) 45(1):30-39.
71. Klivenyi G, Schuhmacher J, Patzelt E, Hauser H, Matys R, Moock M, Regiert T, Maier-Borst W: Gallium-68 chelate imaging of human colon carcinoma xenografts pretargeted with bispecific anti-CD44V6/anti-gallium chelate antibodies. J Nucl Med (1998) 39(10):1769-1776.
72. Schuhmacher J, Kaul S, Klivenyi G, Junkermann H, Magener A, Henze M, Doll J, Haberkorn U, Amelung F, Bastert G: Immunoscintigraphy with positron emission tomography: Gallium-68 chelate imaging of breast cancer pretargeted with bispecific anti-MUC1/anti-Ga chelate antibodies. Cancer Res (2001) 61(9):3712-3717.
73. 68Ga for medical application. J Nucl Med (2007) 48(10):1741-1748.
74. Sharkey RM, Goldenberg DM: Perspectives on cancer therapy with radiolabeled monoclonal antibodies. J Nucl Med (2005) 46(Suppl 1):115S-127S.
75. Koppe MJ, Postema EJ, Aarts F, Oyen WJ, Bleichrodt RP, Boerman OC: Antibody-guided radiation therapy of cancer. Cancer Metastasis Rev (2005) 24(4):539-567.
76. De Decker M, Bacher K, Thierens H, Slegers G, Dierckx RA, De Vos F: In vitro and in vivo evaluation of direct rhenium-188-labeled anti-CD52 monoclonal antibody alemtuzumab for radioimmunotherapy of B-cell chronic lymphocytic leukemia. Nucl Med Biol (2008) 35(5):599-604.
77. 188Re-pharmaceuticals. Adv Drug Deliv Rev (2008) 60(12):1389-1401.
78. Zanzonico PB, Divgi C: Patient-specific radiation dosimetry for radionuclide therapy of liver tumors with intrahepatic artery rhenium-188 lipiodol. Semin Nucl Med (2008) 38(2):S30-S39.
79. 188Re-anti-CD20 in patients with non-Hodgkin's lymphoma: Preliminary experience. Arch Med Res (2008) 39(1):100-109.
80. 213Bi-HuM195 (anti-CD33) in patients with leukemia. J Nucl Med (1999) 40(11):1935-1946.
81. 211At-labeled monoclonal antibodies. Nucl Med Biol (2007) 34(7):779-785.
82. 211At-labeled chimeric antitenascin monoclonal antibody 81C6. J Nucl Med (2008) 49(1):30-38.
83. Miederer M, Scheinberg DA, McDevitt MR: Realizing the potential of the actinium-225 radionuclide generator in targeted α particle therapy applications. Adv Drug Deliv Rev (2008) 60(12):1371-1382. • A potential application of a novel α-emitting nanogenerator for therapy.
84. Michel RB, Rosario AV, Andrews PM, Goldenberg DM, Mattes MJ: Therapy of small subcutaneous B-lymphoma xenografts with antibodies conjugated to radionuclides emitting low-energy electrons. Clin Cancer Res (2005) 11(2 Pt 1):777-786.
85. Mattes MJ, Goldenberg DM: Therapy of human carcinoma xenografts with antibodies to EGFR and HER-2 conjugated to radionuclides emitting low-energy electrons. Eur J Nucl Med Mol Imaging (2008) 35(7):1249-1258.
86. Michel RB, Brechbiel MW, Mattes MJ: A comparison of 4 radionuclides conjugated to antibodies for single-cell kill. J Nucl Med (2003) 44(4):632-640.
87. Kassis AI: Therapeutic radionuclides: Biophysical and radiobiologic principles. Semin Nucl Med (2008) 38(5):358-366.
88. Behr TM, Béhé M, Löhr M, Sgouros G, Angerstein C, Wehrmann E, Nebendahl K, Becker W: Therapeutic advantages of Auger electron- over β-emitting radiometals or radioiodine when conjugated to internalizing antibodies. Eur J Nucl Med (2000) 27(7):753-765.
89. 90Y-labeled CO17-1A Fab′ fragments in a human colonic cancer model. Cancer Res (1999) 59(11):2635-2643.
90. Adams GP, Schier R, McCall AM, Crawford RS, Wolf EJ, Weiner LM, Marks JD: Prolonged in vivo tumor retention of a human diabody targeting the extracellular domain of human HER-2/neu. Br J Cancer (1998) 77(9):1405-1412.
91. Adams GP, Shaller CC, Chappell LL, Wu C, Horak EM, Simmons HH, Litwin S, Marks JD, Weiner LM, Brechbiel MW: Delivery of the α-emitting radioisotope bismuth-213 to solid tumors via single-chain Fv and diabody molecules. Nucl Med Biol (2000) 27(4):339-346.
92. Adams GP, Shaller CC, Dadachova E, Simmons HH, Horak EM, Tesfaye A, Klein-Szanto AJ, Marks JD, Brechbiel MW, Weiner LM: A single treatment of yttrium-90-labeled CHX-A′-C6.5 diabody inhibits the growth of established human tumor xenografts in immunodeficient mice. Cancer Res (2004) 64(17):6200-6206.
93. Sharkey RM, Goldenberg DM: Use of antibodies and immunoconjugates for the therapy of more accessible cancers. Adv Drug Deliv Rev (2008) 60(12):1407-1420.
94. Reardan DT, Meares CF, Goodwin DA, McTigue M, David GS, Stone MR, Leung JP, Bartholomew RM, Frincke JM: Antibodies against metal chelates. Nature (1985) 316(6025):265-268.
95. Goodwin DA, Meares CF, David GF, McTigue M, McCall MJ, Frincke JM, Stone MR, Bartholomew RM, Leung JP: Monoclonal antibodies as reversible equilibrium carriers of radiopharmaceuticals. Int J Rad Appl Instrum B (1986) 13(4):383-391.
96. Goodwin DA, Meares CF, McCall MJ, McTigue M, Chaovapong W: Pretargeted immunoscintigraphy of murine tumors with indium-111-labeled bifunctional haptens. J Nucl Med (1988) 29(2):226-234.
97. Goodwin DA, Meares CF: Pretargeted peptide imaging and therapy. Cancer Biother Radiopharm (1999) 14(3):145-152.
98. Chang CH, Sharkey RM, Rossi EA, Karacay H, McBride W, Hansen HJ, Chatal JF, Barbet J, Goldenberg DM: Molecular advances in pretargeting radioimmunotherapy with bispecific antibodies. Mol Cancer Ther (2002) 1(7):553-563.
99. Stickney DR, Anderson LD, Slater JB, Ahlem CN, Kirk GA, Schweighardt SA, Frincke JM: Bifunctional antibody: A binary radiopharmaceutical delivery system for imaging colorectal carcinoma. Cancer Res (1991) 51(24):6650-6655.
100. Atwell JL, Pearce LA, Lah M, Gruen LC, Kortt AA, Hudson PJ: Design and expression of a stable bispecific scFv dimer with affinity for both glycophorin and N9 neuraminidase. Mol Immunol (1996) 33(17-18):1301-1312.
101. Wu C, Ying H, Grinnell C, Bryant S, Miller R, Clabbers A, Bose S, McCarthy D, Zhu RR, Santora L, Davis-Taber R et al: Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat Biotechnol (2007) 25(11):1290-1297.
102. Shen J, Vil MD, Jimenez X, Zhang H, Iacolina M, Mangalampalli V, Balderes P, Ludwig DL, Zhu Z: Single variable domain antibody as a versatile building block for the construction of IgG-like bispecific antibodies. J Immunol Methods (2007) 318(1-2):65-74.
103. Kontermann RE: Recombinant bispecific antibodies for cancer therapy. Acta Pharmacol Sin (2005) 26(1):1-9.
104. Das D, Suresh MR: Producing bispecific and bifunctional antibodies. Methods Mol Med (2005) 109:329-346.
105. Hayashi H, Asano R, Tsumoto K, Katayose Y, Suzuki M, Unno M, Kodama H, Takemura S, Yoshida H, Makabe K, Imai K et al: A highly effective and stable bispecific diabody for cancer immunotherapy: Cure of xenografted tumors by bispecific diabody and T-LAK cells. Cancer Immunol Immunother (2004) 53(6):497-509.
106. Lu D, Jimenez X, Zhang H, Atkins A, Brennan L, Balderes P, Bohlen P, Witte L, Zhu Z: Di-diabody: A novel tetravalent bispecific antibody molecule by design. J Immunol Methods (2003) 279(1-2):219-232.
107. Asano R, Kudo T, Nishimura Y, Makabe K, Hayashi H, Suzuki M, Tsumoto K, Kumagai I: Efficient construction of a diabody using a refolding system: Anti-carcinoembryonic antigen recombinant antibody fragment. J Biochem (2002) 132(6):903-909.
108. Kipriyanov SM: Generation and characterization of bispecific tandem diabodies for tumor therapy. Methods Mol Biol (2003) 207:323-333.
109. Rossi EA, Chang CH, Losman MJ, Sharkey RM, Karacay H, McBride W, Cardillo TM, Hansen HJ, Qu Z, Horak ID, Goldenberg DM: Pretargeting of carcinoembryonic antigen-expressing cancers with a trivalent bispecific fusion protein produced in myeloma cells. Clin Cancer Res (2005) 11(19 Pt 2):7122s-7129s.
110. Rossi EA, Sharkey RM, McBride W, Karacay H, Zeng L, Hansen HJ, Goldenberg DM, Chang CH: Development of new multivalent-bispecific agents for pretargeting tumor localization and therapy. Clin Cancer Res (2003) 9(10 Pt 2):3886S-3896S.
111. Karacay H, Sharkey RM, McBride WJ, Griffiths GL, Qu Z, Chang K, Hansen HJ, Goldenberg DM: Pretargeting for cancer radioimmunotherapy with bispecific antibodies: Role of the bispecific antibody's valency for the tumor target antigen. Bioconjug Chem (2002) 13(5):1054-1070.
112. Rossi EA, Goldenberg DM, Cardillo TM, McBride WJ, Sharkey RM, Chang CH: Stably tethered multifunctional structures of defined composition made by the dock-and-lock method for use in cancer targeting. Proc Natl Acad Sci USA (2006) 103(18):6841-6846.
113. Goldenberg DM, Rossi EA, Sharkey RM, McBride WJ, Chang CH: Multifunctional antibodies by the dock-and-lock method for improved cancer imaging and therapy by pretargeting. J Nucl Med (2008) 49(1):158-163.
114. Chang CH, Rossi EA, Goldenberg DM: The dock-and-lock method: A novel platform technology for building multivalent, multifunctional structures of defined composition with retained bioactivity. Clin Cancer Res (2007) 13(18 Pt 2):5586s-5591s.
115. Chen X, Dou S, Liu G, Liu X, Wang Y, Chen L, Rusckowski M, Hnatowich DJ: Synthesis and in vitro characterization of a dendrimer-MORF conjugate for amplification pretargeting. Bioconjug Chem (2008) 19(8):1518-1525.
116. Liu G, Dou S, Pretorius PH, Liu X, Rusckowski M, Hnatowich DJ: Pretargeting CWR22 prostate tumor in mice with MORF-B72.3 antibody and radiolabeled cMORF. Eur J Nucl Med Mol Imaging (2008) 35(2):272-280.
117. He J, Rusckowski M, Wang Y, Dou S, Liu X, Zhang S, Liu G, Hnatowich DJ: Optical pretargeting of tumor with fluorescent MORF oligomers. Mol Imaging Biol (2007) 9(1):17-23.
118. 188Re-radiolabeled phosphorodiamidate morpholino oligomer, a synthetic DNA analog. Clin Cancer Res (2006) 12(16):4958-4964.
119. Hnatowich DJ, Virzi F, Rusckowski M: Investigations of avidin and biotin for imaging applications. J Nucl Med (1987) 28(8):1294-1302.
120. Hnatowich DJ. The in vivo uses of streptavidin and biotin: A short progress report. Nucl Med Commun (1994) 15(8):575-577.
121. Zhang M, Zhang Z, Garmestani K, Schultz J, Axworthy DB, Goldman CK, Brechbiel MW, Carrasquillo JA, Waldmann TA: Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts. Proc Natl Acad Sci USA (2003) 100(4):1891-1895.
122. Cheung NK, Modak S, Lin Y, Guo H, Zanzonico P, Chung J, Zuo Y, Sanderson J, Wilbert S, Theodore LJ, Axworthy DB et al: Single-chain Fv-streptavidin substantially improved therapeutic index in multistep targeting directed at disialoganglioside GD2. J Nucl Med (2004) 45(5):867-877.
123. Sato N, Hassan R, Axworthy DB, Wong KJ, Yu S, Theodore LJ, Lin Y, Park L, Brechbiel MW, Pastan I, Paik CH et al: Pretargeted radioimmunotherapy of mesothelin-expressing cancer using a tetravalent single-chain Fv-streptavidin fusion protein. J Nucl Med (2005) 46(7):1201-1209.
124. Forero-Torres A, Shen S, Breitz H, Sims RB, Axworthy DB, Khazaeli MB, Chen KH, Percent I, Besh S, LoBuglio AF, Meredith RF: Pretargeted radioimmunotherapy (RIT) with a novel anti-TAG-72 fusion protein. Cancer Biother Radiopharm (2005) 20(4):379-390.
125. Buchsbaum DJ, Khazaeli MB, Axworthy DB, Schultz J, Chaudhuri TR, Zinn KR, Carpenter M, LoBuglio AF: Intraperitoneal pretarget radioimmunotherapy with CC49 fusion protein. Clin Cancer Res (2005) 11(22):8180-8185.
126. Lin Y, Pagel JM, Axworthy D, Pantelias A, Hedin N, Press OW: A genetically engineered anti-CD45 single-chain antibody-streptavidin fusion protein for pretargeted radioimmunotherapy of hematologic malignancies. Cancer Res (2006) 66(7):3884-3892.
127. Pagel JM, Lin Y, Hedin N, Pantelias A, Axworthy D, Stone D, Hamlin DK, Wilbur DS, Press OW: Comparison of a tetravalent single-chain antibody-streptavidin fusion protein and an antibody-streptavidin chemical conjugate for pretargeted anti-CD20 radioimmunotherapy of B-cell lymphomas. Blood (2006) 108(1):328-336.
128. Paganelli G, Malcovati M, Fazio F: Monoclonal antibody pretargetting techniques for tumor localization: The avidin-biotin system. International Workshop on Techniques for Amplification of Tumour Targetting. Nucl Med Commun (1991) 12(3):211-234.
129. 90Y radioimmunotherapy in a mouse xenograft model. J Immunother (1994) 16:158.
130. Axworthy DB, Reno JM, Hylarides MD, Mallett RW, Theodore LJ, Gustavson LM, Su F, Hobson LJ, Beaumier PL, Fritzberg AR: Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. Proc Natl Acad Sci USA (2000) 97(4):1802-1807.
131. Press OW, Corcoran M, Subbiah K, Hamlin DK, Wilbur DS, Johnson T, Theodore L, Yau E, Mallett R, Meyer DL, Axworthy D: A comparative evaluation of conventional and pretargeted radio-immunotherapy of CD20-expressing lymphoma xenografts. Blood (2001) 98(8):2535-2543.
132. Pagel JM, Hedin N, Subbiah K, Meyer D, Mallet R, Axworthy D, Theodore LJ, Wilbur DS, Matthews DC, Press OW: Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas. Blood (2003) 101(6):2340-2348.
133. Subbiah K, Hamlin DK, Pagel JM, Wilbur DS, Meyer DL, Axworthy DB, Mallett RW, Theodore LJ, Stayton PS, Press OW: Comparison of immunoscintigraphy, efficacy, and toxicity of conventional and pretargeted radioimmunotherapy in CD20-expressing human lymphoma xenografts. J Nucl Med (2003) 44(3):437-445.
134. Sharkey RM, Karacay H, Cardillo TM, Chang CH, McBride WJ, Rossi EA, Horak ID, Goldenberg DM: Improving the delivery of radionuclides for imaging and therapy of cancer using pretargeting methods. Clin Cancer Res (2005) 11(19 Pt 2): 7109s-7121s.
135. 131I-labeled bivalent hapten. J Nucl Med (2000) 41(3):480-487.
136. 2 and pretargeted bivalent hapten and evaluation of repeated injections. Clin Cancer Res (1999) 5(Suppl 10):3183s-3189s.
137. Kraeber-Bodéré F, Faibre-Chauvet A, Saï-Maurel C, Gautherot E, Fiche M, Campion L, Le Boterff J, Barbet J, Chatal JF, Thédrez P: Bispecific antibody and bivalent hapten radioimmunotherapy in CEA-producing medullary thyroid cancer xenograft. J Nucl Med (1999) 40(1):198-204.
138. Gautherot E, Bouhou J, Le Doussal JM, Manetti C, Martin M, Rouvier E,
139. Karacay H, Brard PY, Sharkey RM, Chang CH, Rossi EA, McBride WJ, Ragland DR, Horak ID, Goldenberg DM: Therapeutic advantage of pretargeted radioimmunotherapy using a recombinant bispecific antibody in a human colon cancer xenograft. Clin Cancer Res (2005) 11(21):7879-7885.
140. Sharkey RM, Karacay H, Litwin S, Rossi EA, McBride WJ, Chang CH, Goldenberg DM: Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody. Cancer Res (2008) 68(13):5282-5290.
141. Graves SS, Dearstyne E, Lin Y, Zuo Y, Sanderson J, Schultz J, Pantalias A, Gray D, Axworthy D, Jones HM, Auditore-Hargreaves K: Combination therapy with pretarget CC49 radioimmunotherapy and gemcitabine prolongs tumor doubling time in a murine xenograft model of colon cancer more effectively than either monotherapy. Clin Cancer Res (2003) 9(10 Pt 1): 3712-3721.
142. Kraeber-Bodéré F, Saï-Maurel C, Campion L, Faivre-Chauvet A, Mirallié E, Chérel M, Supiot S, Barbet J, Chatal JF, Thédrez P: Enhanced antitumor activity of combined pretargeted radioimmunotherapy and paclitaxel in medullary thyroid cancer xenograft. Mol Cancer Ther (2002) 1(4):267-274.
143. Paganelli G, Magnani P, Fazio F: Pretargeting of carcinomas with the avidin-biotin system. Int J Biol Markers (1993) 8(3):155-159.
144. Goldenberg DM, Sharkey RM, Paganelli G, Barbet J, Chatal JF: Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J Clin Oncol (2006) 24(5):823-834. • A review of preclinical and clinical pretargeted imaging and therapy.
145. Le Doussal JM, Martin M, Gautherot E, Delaage M, Barbet J: In vitro and in vivo targeting of radiolabeled monovalent and divalent haptens with dual specificity monoclonal antibody conjugates: Enhanced divalent hapten affinity for cell-bound antibody conjugate. J Nucl Med (1989) 30(8):1358-1366.
146. 188Re-labeled peptide. Bioconjug Chem (2000) 11(6):842-854.
147. 131I-labeled bivalent hapten in a phase I optimization clinical trial. J Nucl Med (2006) 47(2):247-255.
148. Morandeau L, Benoist E, Loussouarn A, Ouadi A, Lesaec P, Mougin M, Faivre-Chauvet A, Le Boterff J, Chatal JF, Barbet J, Gestin JF: Synthesis of new bivalent peptides for applications in the Affinity Enhancement System. Bioconjug Chem (2005) 16(1):184-193.
149. Sharkey RM, McBride WJ, Karacay H, Chang K, Griffiths GL, Hansen HJ, Goldenberg DM: A universal pretargeting system for cancer detection and therapy using bispecific antibody. Cancer Res (2003) 63(2):354-363.
150. Janevik-Ivanovska E, Gautherot E, Hillairet de Boisferon M, Cohen M, Milhaud G, Tartar A, Rostene W, Barbet J, Gruaz-Guyon A: Bivalent hapten-bearing peptides designed for iodine-131 pretargeted radioimmunotherapy. Bioconjug Chem (1997) 8(4):526-533.
151. 124I-labeled hapten-peptide. J Nucl Med (2006) 47(10):1678-1688.
152. Sharkey RM, Karacay H, Vallabhajosula S, McBride WJ, Rossi EA, Chang CH, Goldsmith SJ, Goldenberg DM: Metastatic human colonic carcinoma: Molecular imaging with pretargeted SPECT and PET in a mouse model. Radiology (2008) 246(2):497-507.
153. McBride WJ, Goldenberg DM: A new method of labeling peptides with F-18 via a metal ligand. J Nucl Med (2008) 49(Suppl 1):97P.
154. Barbet J, Peltier P, Bardet S, Vuillez JP, Bachelot I, Denet S, Olivier P, Leccia F, Corcuff B, Huglo D, Proye C et al: Radioimmunodetection of medullary thyroid carcinoma using indium-111 bivalent hapten and anti-CEA x anti-DTPA-indium bispecific antibody. J Nucl Med (1998) 39(7):1172-1178.
155. Vuillez JP, Moro D, Brichon PY, Rouvier E, Brambilla E, Barbet J, Peltier P, Meyer P, Sarrazin R, Brambilla C: Two-step immunoscintigraphy for non-small-cell lung cancer staging using a bispecific anti-CEA/anti-indium-DTPA antibody and an indium-111-labeled DTPA dimer. J Nucl Med (1997) 38(4):507-511.
156. 111In-labelled bivalent hapten and a bispecific antibody conjugate. Nucl Med Commun (1994) 15(12):972-980.
157. Le Doussal JM, Chetanneau A, Gruaz-Guyon A, Martin M, Gautherot E, Lehur PA, Chatal JF, Delaage M, Barbet J: Bispecific monoclonal antibody-mediated targeting of an indium-111-labeled DTPA dimer to primary colorectal tumors: Pharmacokinetics, biodistribution, scintigraphy and immune response. J Nucl Med (1993) 34(10):1662-1671.
158. Moffat FL Jr, Pinsky CM, Hammershaimb L, Petrelli NJ, Patt YZ, Whaley FS, Goldenberg DM: Clinical utility of external immunoscintigraphy with the IMMU-4 technetium-99m Fab′ antibody fragment in patients undergoing surgery for carcinoma of the colon and rectum: Results of a pivotal, phase III trial. The Immunomedics Study Group. J Clin Oncol (1996) 14(8):2295-2305.
159. Sharkey RM, Cardillo TM, Rossi EA, Chang CH, Karacay H, McBride WJ, Hansen HJ, Horak ID, Goldenberg DM: Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibody. Nat Med (2005) 11(11):1250-1255.
160. 64Cu for tumor imaging and therapy. J Nucl Med (2003) 44(8):1284-1292.
161. Schuhmacher J, Klivenyi G, Kaul S, Henze M, Matys R, Hauser H, Clorius J: Pretargeting of human mammary carcinoma xenografts with bispecific anti-MUC1/anti-Ga chelate antibodies and immunoscintigraphy with PET. Nucl Med Biol (2001) 28(7):821-828.
162. 64Cu-labeled streptavidin following pretargeting of phosphatidylserine with biotinylated annexin-V. Eur J Nucl Med Mol Imaging (2007) 34(2):247-258.
163. Boerman O, Sharkey R, Franssen G, Chang C-H, Rossi E, McBride W, Schoffelen R, van der Graaf W, Oyen W, Goldenberg D: Pretargeted ImmunoPET imaging of CEA-expressing tumors using a Ga-68-labeled peptide. J Nucl Med (2008) 49(Suppl 1):52P.
164. Knox SJ, Goris ML, Tempero M, Weiden PL, Gentner L, Breitz H, Adams GP, Axworthy D, Gaffigan S, Bryan K, Fisher DR et al: Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer. Clin Cancer Res (2000) 6(2):406-414.
165. Shen S, Forero A, LoBuglio AF, Breitz H, Khazaeli MB, Fisher DR, Wang W, Meredith RF: Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies. J Nucl Med (2005) 46(4):642-651.
166. Paganelli G, Grana C, Chinol M, Cremonesi M, De Cicco C, De Braud F, Robertson C, Zurrida S, Casadio C, Zoboli S, Siccardi AG et al: Antibody-guided three-step therapy for high-grade glioma with yttrium-90 biotin. Eur J Nucl Med (1999) 26(4):348-357.
167. 90Y-biotin in glioma patients: Phase I study and preliminary therapeutic results. Cancer Biother Radiopharm (2001) 16(3):227-235.
168. Grana C, Chinol M, Robertson C, Mazzetta C, Bartolomei M, De Cicco C, Fiorenza M, Gatti M, Caliceti P, Paganelli G: Pretargeted adjuvant radioimmunotherapy with yttrium-90-biotin in malignant glioma patients: A pilot study. Br J Cancer (2002) 86(2):207-212.
169. 90Y radioimmunotherapy (RIT) in recurrent glioblastoma. J Neurooncol (2005) 72(2):125-131.
170. 90Y-biotin radioimmunotherapy and temozolomide. Q J Nucl Med Mol Imaging (2004) 48(3):220-228.
171. 90Y-biotin? Gynecol Oncol (2004) 93(3):691-698.
172. Chatal JF, Campion L, Kraeber-Bodéré F, Bardet S, Vuillez JP, Charbonnel B, Rohmer V, Chang CH, Sharkey RM, Goldenberg DM, Barbet J: Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: A collaborative study with the French Endocrine Tumor Group. J Clin Oncol (2006) 24(11):1705-1711.
173. Pagel JM, Pantelias A, Hedin N, Wilbur S, Saganic L, Lin Y, Axworthy D, Hamlin DK, Wilbur DS, Gopal AK, Press OW: Evaluation of CD20, CD22, and HLA-DR targeting for radioimmunotherapy of B-cell lymphomas. Cancer Res (2007) 67(12):5921-5928.
174. Sharkey RM, Karacay H, Chang CH, McBride WJ, Horak ID, Goldenberg DM: Improved therapy of non-Hodgkin's lymphoma xenografts using radionuclides pretargeted with a new anti-CD20 bispecific antibody. Leukemia (2005) 19(6):1064-1069.
175. Press OW, Unger JM, Braziel RM, Maloney DG, Miller TP, Leblanc M, Fisher RI: Phase II trial of CHOP chemotherapy followed by tositumomab/iodine-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: Five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol (2006) 24(25):4143-4149.
176. Fisher RI: Overview of Southwest Oncology Group Clinical Trials in non-Hodgkin lymphoma. S0016. A phase III trial of CHOP vs CHOP + rituximab vs CHOP + iodine-131-labeled monoclonal anti-B1 antibody (tositumomab) for treatment of newly diagnosed follicular NHL. Clin Adv Hematol Oncol (2005) 3(7):544-546.
177. Zhang MM, Gopal AK: Radioimmunotherapy-based conditioning regimens for stem cell transplantation. Semin Hematol (2008) 45(2):118- 125.
178. Zinzani PL, Tani M, Pulsoni A, Gobbi M, Perotti A, De Luca S, Fabbri A, Zaccaria A, Voso MT, Fattori P, Guardigni L et al: Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: A phase II nonrandomised trial (FLUMIZ). Lancet Oncol (2008) 9(4):352-358.
179. Zinzani PL, Tani M, Fanti S, Stefoni V, Musuraca G, Castellucci P, Marchi E, Farsad M, Fina M, Pellegrini C, Alinari L et al: A phase II trial of CHOP chemotherapy followed by yttrium-90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients. Ann Oncol (2008) 19(4):769-773.
180. Molina A, Krishnan A, Fung H, Flinn IW, Inwards D, Winter JN, Nademanee A: Use of radioimmunotherapy in stem cell transplantation and posttransplantation: Focus on yttrium-90 ibritumomab tiuxetan. Curr Stem Cell Res Ther (2007) 2(3):239-248.
181. 90Y-ibritumomab tiuxetan in patients with relapsed B-cell non-Hodgkin's lymphoma following high-dose chemotherapy and autologous stem cell transplantation. Leuk Lymphoma (2007) 48(4):683-690.
182. Shimoni A, Zwas ST, Oksman Y, Hardan I, Shem-Tov N, Yerushalmi R, Avigdor A, Ben-Bassat I, Nagler A: Yttrium-90-ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemorefractory aggressive non-Hodgkin's lymphoma. Exp Hematol (2007) 35(4):534-540.